MAPT and Dravet syndrome: Intranasal treatment of Ts65Dn mice with rapamycin, which targets the mTOR pathway, normalizes raised abundance of phosphorylated tau (Tramutola et al., 2018; Di Domenico et al., 2019), implicating mTOR signaling in altered tau biology in DS.